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Quantifying Allodynia in Patients Suffering From Unilateral
Neuropathic Pain Using Von Frey Monofilaments
Doeke Keizer, MD,* Marten van Wijhe, MD, PhD,* Wendy J. Post, PhD,w
and J. Mark K. H. Wierda, MD, PhD*
Objectives: The aim of this study is to investigate whether
quantitative sensory testing with Von Frey monoﬁlaments
(VFMs) can be used for the quantiﬁcation of allodynia in
patients with chronic neuropathic pain, and how the pain
threshold of aﬀected skin diﬀers from healthy skin.
Methods:Using VFMs, we aimed to determine the pain threshold
in 22 patients suﬀering from allodynia as a consequence of a
chronic unilateral neuropathic pain syndrome. We performed
quantitative sensory testing according to the Method of Limits
protocol. We used the patient’s own contralateral side and 5
healthy control participants to obtain reference values.
Results: On the aﬀected side, we found in 20 out of 22 patients
that the pain threshold could be determined with the monoﬁla-
ments. On average, these 20 patients indicated pain upon the
application of monoﬁlament with logarithmic nr. 4.56, whereas
no pain threshold could be determined on the contralateral,
unaﬀected side, and in the healthy control participants for any
monoﬁlament.
Discussion: We showed that although etiology and pathophy-
siology of allodynia vary individually, with VFMs the clinical
symptom allodynia can be quantiﬁed in a simple and practical
fashion in almost all patients.
Key Words: allodynia, neuropathic pain, Von Frey monoﬁla-
ment, threshold
(Clin J Pain 2007;23:85–90)
About 1% to 1.5% of the population in westerncountries suﬀers from some form of neuropathic
pain.1 Neuropathic pain is a common symptom of various
conditions, ranging from diabetic polyneuropathy to the
nerve entrapment by tumors. The pathophysiology of
neuropathic pain is extremely complex and diﬀers
amongst various pain syndromes.
Stimulus-evoked pain is a phenomenon that can be
frequently observed in patients with neuropathic pain and
includes allodynia and hyperalgesia.2–5 The International
Association for the Study of Pain (IASP) deﬁnes
allodynia as pain due to a stimulus, which does not
normally provoke pain, and hyperalgesia as an increased
response to a stimulus, which is normally painful.6
Allodynia may well be one of the most disabling physical
symptoms in neuropathic pain.7,8 Allodynia is manifested
in pain resulting for example from contact between
clothing and skin, or between water and skin when
taking a shower.
The clinical symptoms allodynia and hyperalgesia
can be used to evaluate the eﬀect of therapy aimed to
reduce neuropathic pain. Neuropathic pain is notoriously
diﬃcult to alleviate, especially when compared with
nociceptive pain.9,10 In general, evaluation of the eﬀect of
therapeutic interventions is complicated by the fact that the
variable, that is pain, is subjective in nature. Whereas
subjective pain scores can be obtained by means of the
Visual Analog Scale (VAS) or the Numeric Rating Scale
(NRS), more objective information concerning the severity
of neuropathic pain can be obtained with quantitative
sensory testing (QST) of allodynia or hyperalgesia.
Von Frey monoﬁlaments (VFMs) are frequently
used as a means of QST to assess perception thresholds of
sensory function at speciﬁc body sites, for example, for
quantifying hypoesthesia in diabetic polyneuropathy.11,12
In pain research, VFMs can be used to administer painful
stimuli on hypersensitive skin in human experimental
pain conditions or to determine the size of the hypersen-
sitive skin area.13–15 In rodents the withdrawal responses
of painful hindpaws can be determined with VFMs.16,17
When used in a standardized fashion, application of
VFMs provides the clinical investigator with practical,
reproducible, and reliable test results.18,19 The most
important condition is that measurement with VFMs
should occur according to a uniform and standardized
protocol.20 In the presence of stimulus-evoked pain of the
skin, apart from the perception threshold, a pain thresh-
old can be determined as well.
The aim of this study was to investigate whether
QST with VFMs can be used to quantify stimulus-evoked
pain in patients with chronic neuropathic pain, and how
these thresholds diﬀer from the healthy skin. QST withCopyright r 2006 by Lippincott Williams & Wilkins
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VFMs can be used for measuring stimulus-evoked pain
irrespective of the underlying pathophysiologic mechan-
isms. Whereas thin VFMs stimulate low threshold
Ab-ﬁbers, thick VFMs also recruit Ad-ﬁber nociceptors
or even C-ﬁber nociceptors.5,21–24 The extent in which the
diﬀerent nerve ﬁbers are involved in the—subjective—
sensation that is perceived by the participant cannot be
ascertained.
We present the mean value of pain thresholds, as
determined with VFMs using the Method of Limits,25,26
in 20 patients suﬀering from stimulus-evoked pain as a
consequence of a unilateral neuropathic pain syndrome.
We will argue that this stimulus-evoked pain is in
accordance with the IASP deﬁnition of allodynia.
The pain threshold is deﬁned as the logarithmic number
of a VFM, which expresses the force exerted by this VFM
that is reported as painful by the participant. QST on the
patient’s own contralateral, unaﬀected side was
performed to acquire appropriate reference values.20
Furthermore, to exclude the possibility that a relative
hypalgesia might occur on the unaﬀected skin, we also
performed QST in 5 healthy participants. To our best
knowledge, a mean pain threshold of allodynia in patients
with chronic neuropathic pain has not been published.
In this study, we demonstrate that the symptom of
allodynia, irrespective of the underlying pathophysiologic
mechanisms, is quantiﬁable in a simple and practical way
with the use of VFMs.
MATERIALS AND METHODS
Patients and Control Participants
Twenty-two patients suﬀering from unilateral neuro-
pathic pain and stimulus-evoked pain participated in
this study after giving their informed consent. The
study was approved by the Medical Ethics Committee
of the University Hospital in Groningen. In these
patients, history and physical examination revealed the
presence of allodynia, which was regarded to be present
when a normally nonpainful stimulus of any kind was
considered painful by the patient. At the time of the
inclusion, no distinction was made in type of stimulus-
evoked pain or in medical diagnosis as a result of which
the pain syndrome had arisen or in duration of the pain
syndrome.
Patients with polyneuropathy and or diabetes
mellitus were excluded, as those conditions may inﬂuence
the outcome of QST. Drug addiction or psychiatric
diseases were also considered exclusion factors. Partici-
pants continued their (analgesic) medication.
Five control participants, who did not suﬀer from
pain of any kind and did not use any medication, were
also included after they signed an informed consent.
Originally, we intended to include 10 healthy participants,
however, after the study had been performed in
5 participants, there was no variation of the results,
therefore we decided to include no more participants.
Experimental Setting
All patients underwent the experiment in a quiet
room with a constant temperature of 201C to 221C. Each
of the examinations was carried out by the same
investigator (D.K). To acclimatize, the patients were
present in the room for 10 to 15 minutes before the actual
QST procedures. During this time, they were informed
about the procedure and the monoﬁlaments were
demonstrated to familiarize the patients with the proce-
dure. Subsequently, the patients underwent the experi-
ment lying on an examination table. The patient was
asked to point out the skin area where the stimulus-
evoked pain was perceived as the most intense. The
punctum maximum was marked by a small square
(±1 cm2) drawn on the skin. The corresponding spot
on the contralateral side of the body was marked
similarly.
QST of the control participants was performed on
the dorsum of the hand above the ﬁrst interosseus muscle
on the left or right hand; allocated at random. Again,
measurements took place within a square drawn on the
skin, in the same manner as the patients.
QST With VFMs
A set consisting of 20 nylon VFMs with constant
length and increasing diameter of the ﬁrm Touch Test
(North Coast Medical, Inc; Morgan Hill) was used. When
applied, these VFMs exert a constant force onto the
tested skin. The bending of the VFM reduces measure-
ment outcome artifacts resulting from movement or
trembling of the examiner’s hand.18 The VFMs are
calibrated in a logarithmic scale from 0.008 to 300 g
(0.08 to 2943mN), within a 5% standard deviation.
Numbers on each monoﬁlament ranging from 1.65 to
6.65, represent the common logarithm of 10 times the
force in milligrams.27
The VFMs were applied in increasing thickness on
the aﬀected and nonaﬀected side successively—in a
randomized sequence—until a pain threshold was de-
tected. This method is called the ‘‘Method of Limits.’’25,26
The patient was asked to give a clear verbal signal when
the stimulus was perceived as painful. We asked the
patients to pay speciﬁc attention to the pricking sensa-
tions evoked by stimulation with the monoﬁlaments;
would they consider this sensation to be painful or not?
Each VFM was applied 3 times, with approximately 10
seconds between 2 successive stimuli, to avoid temporal
summation.23,28,29 Subsequently, the procedure was re-
peated on the contralateral side.
The VFM was applied perpendicularly to the skin
surface for approximately 2 seconds, until a bending of
3 to 5mm of the VFM was produced. Patients kept their
eyes closed during the investigation to avoid visual
feedback concerning the stimuli.
The pain threshold was deﬁned as the logarithmic
number on the VFM in which at least 2 out of 3
applications on the aﬀected side resulted in the perception,
and subsequent reporting of pain, the so-called ‘‘appear-
ance’’-threshold. 20,25,30 Once a pain threshold was
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reached, we asked the patients to rate the amount of pain
that was induced by the stimulus on a NRS. Next,
QST was stopped. To exclude interference of learning
eﬀects, the side on which the examination began was
randomized.
Data Analysis
The mean value of the pain threshold, as measured
with VFMs was determined, and the standard deviation.
The pain threshold is expressed as the number of the
logarithmic scale mentioned earlier.
RESULTS
The group of included patients consisted of 6 men
and 16 women, with a mean age of 49.2 years (range 24 to
78 y). The duration of their underlying pain syndromes
varied from only a few months to several decades. The
neuropathic pain was either the result of trauma, surgery,
or herpes zoster, or was due to chronic complex regional
pain syndrome type 1 (Table 1). The group of 5 control
participants consisted of 2 men and 3 women, with a
mean age of 40.0 years (range 25 to 50 y).
At the time of inclusion, 6 patients did not use any
medication, 11 used a tricyclic antidepressant and/or
an antiepileptic drug, sometimes in combination with
analgesics. None of the control participants were under
the inﬂuence of medication at the time of inclusion. In
the case of the patients, the procedure of QST took
approximately 5 to 10 minutes, which was about twice
as long compared to the control participants.
In 2 of the 22 patients, a pain threshold could not
be measured using VFMs. Although the presence of
stimulus-evoked pain had been demonstrated during the
examination of the aﬀected skin area, no pain threshold
was reached with the application of any VFM.
Figure 1 illustrates the various pain thresholds as
determined in the remaining 20 patients. All pain
thresholds were above VFM log nr. 4.08 (9.8mN) and
under VFM log nr. 4.93 (78.5mN). A pain threshold
could neither be determined on the nonaﬀected side for
any VFM, nor in any of the control participants. The
patients indicated that the transition from nonpainful
sensation to painful sensation was clearly noticeable;
the NRS scores of the stimulus-evoked pain averaged 6.8
(range 4 to 9).
TABLE 1. Characteristics of Participating Patients
Patient







1 41 M Lower abdomen Appendectomy 300 4 None
2 59 F Left ankle Bimalleolar fracture 65 6 Naproxen, tramadol
3 34 F Right ﬂank (side) Nephrectomy 55 5 Amitriptyline
4 69 F Right Th4 dermatome Herpes zoster 4 6 Amitriptyline
5 37 F Dorsal right upper arm Excision melanoma 5 7 None
6 27 F Left dorsal foot Excision neuroﬁbroma 100 7 Ibuprophen
7 54 M C2 dermatome right Excision ﬁbroma 72 4 Gabapentin
8 39 M Left leg CRPS type 1 44 7 Diclofenac, acetominophen
9 57 F Right area of infraorbital
nerve
Orbital fracture 38 8 Tramadol, oxycodone,
amitriptyline, gabapentin,
oxazepam
10 56 M Right C6 dermatome Spontaneous 22 8 None
11 58 M Left leg CRPS type 1 30 9 None
12 24 F Right leg CRPS type 1 115 6 None





14 40 F Left arm CRPS type 1 6 7 Amitriptyline, tramadol,
acetominophen
15 48 F Area of lateral cutaneous
nerve
Surgery in right groin 30 7 Gabapentin
16 72 F Left armpit Excision lymph node 7 5 Acetominophen,
ibuprophen, amitriptyline,
temazepam
17 26 F Right wrist CRPS type 1 18 7 Diclofenac, acetominophen,
ibuprophen
18 72 F Right Th8 dermatome Herpes zoster 16 8 Acetominophen, tramadol,
gabapentin, oxazepam
19 28 F Left leg CRPS type 1 1 8 Tramadol, amitriptyline,
gabapentin
20 78 F Right L3 Dermatome Herpes zoster 8 8 Gabapentin
21 54 M Left lateral heel Fracture both calcanei 43 8 Amitriptyline, clomipramine,





In the last 2 patients (nr. 21 and 22), no pain threshold could be measured with VFMs.
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In this study, we found a mean pain threshold
corresponding with the logarithmic number 4.47,
(SD=0.25) on the aﬀected skin, which signiﬁes that the
patients suﬀering from stimulus-evoked pain will on
average experience VFM with log nr. 4.56 (39.2mN) as
painful (Fig. 1). The standard deviation of 0.25 corre-
sponds with 2 VFMs thinner or thicker than the VFM
with log nr. 4.56.
DISCUSSION
Despite the heterogeneous character of the patients
and their neuropathic pain syndromes, we showed that
stimulus-evoked pain is quantiﬁable using VFMs—within
a narrow range of deviation—in 20 of 22 patients. On
average, these 20 patients indicated pain upon the
application of VFM with log nr. 4.56, whereas no pain
threshold could be determined on the contralateral,
unaﬀected side for any VFM or in any of the control
participants. Several aspects of this method of QST need
further consideration.
Although thick VFMs evoke a pricking sensation
on unaﬀected skin, none of the patients or control
participants described this pricking sensation as pain.
Therefore, we decided to call the patient’s stimulus-
evoked pain ‘‘allodynia’’ in stead of (pinprick or
punctate) ‘‘hyperalgesia.’’ The IASP deﬁnition of pain
also explicitly states that ‘‘experiences which resemble
pain but are not unpleasant, for example pricking, should
not be called pain.’’6
Despite the presence of allodynia, which had been
established during history taking and physical examina-
tion, a pain threshold could not be determined in 2 of the
22 patients. Several explanations may account for this
ﬁnding. First, a primarily psychogenic cause of allodynia
or insuﬃcient cooperation may frustrate the outcome of
QST by inconsistent reporting.25 Second, it is not exactly
known to what extent the diﬀerent subtypes of aﬀerent
nerve ﬁbers—Ab, Ad, or C ﬁbers—are stimulated by
the various VFMs.5,21–24 Because the involvement of one
of these subtypes of aﬀerent nerve ﬁbers may predomi-
nate in a patient’s clinical symptom of allodynia, it is
possible that the dominant subtype of aﬀerent ﬁber is not
activated suﬃciently with VFMs to reach a pain thresh-
old. To elucidate the extent in which the diﬀerent types of
aﬀerent ﬁber are involved in the perception of the
diﬀerent VFMs, future studies using diﬀerential nerve
blocks would be needed.
We believe that wind-up-like pain or temporal
summation did not inﬂuence the outcome of our
measurements, because of the intervals of over 10 seconds
between stimuli with the successive stimuli (0.1Hz).
Wind-up-like pain, lowering of the pain threshold, has
shown to be evoked when stimuli are applied at a
frequency of 0.3Hz or higher.23,28,29 We assumed that no
signiﬁcant loss of attention occurred during the brief
period when QST was performed.
Apart from QST, VFMs have also been deployed
for investigating the qualitative aspects of sensory
function that is to determine the presence of hyposensi-
bility or hypersensibility. In patients with diabetic
polyneuropathy, VFMs can be used to assess whether
nerve function is compromised, as is described by Olaleye
et al11 and Perkins et al.12 In these 2 studies, the hallux of
each foot was stimulated with one speciﬁc VFM, while
the patient was asked to respond if the stimulus was
perceived. This screening method enables clinicians to
rapidly assess the presence of impaired sensory function.
However, no information is obtained concerning the
severity of the sensory impairment.
The severity of sensory dysfunction can be deter-
mined in various manners. The ﬁrst method is to measure
or ‘‘map’’ the area of altered sensibility, by changing the
location where the VFM is applied on the skin. A change
in the size of the skin area where the stimulus-evoked pain
is located, can aid in evaluating the eﬀect of therapeutic
interventions.28,31–33
An alternative method to quantify the severity of
stimulus-evoked pain, is to apply a stimulus following
which the patient is asked to rate the severity of pain on
a VAS or NRS.31,34,35 The major disadvantage of this
method of QST, however, is that VAS and NRS scores
are highly subjective.
Finally, the smallest stimulus intensity needed to
evoke a response can be determined. For example,
Voerman et al27 measured sensory detection thresholds
in patients with chronic cervicobrachialgia, by applying
FIGURE 1. Exerted force for each Von Frey monofilament and
corresponding number of patients that considered the
application of the VFM as painful.
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VFMs of increasing thickness on the skin according to the
Method of Limits protocol, after these patients had
undergone a diagnostic dorsal root blockade. The
patients were asked to respond as soon as the stimulus
was felt. The detection threshold was expressed as the
physical force exerted by the smallest monoﬁlament that
evoked the patient’s response. Similarly, Wallace et al31
measured both sensory detection thresholds and pain
thresholds with VFMs after infusion of analgesics in
healthy participants in whom pain had been induced with
intradermal capsaicin injections. Although we used a
comparable design in our study, several diﬀerences in
methodology warrant further discussion. Wallace and
coworkers used VFMs to measure both sensory detection
thresholds and pain thresholds; we only measured pain
thresholds. They selected the monoﬁlaments at
random, whereas we applied always the same ascending
order of monoﬁlaments. In both studies, the pain
threshold was expressed as the smallest force needed to
evoke a response from the participant, however, Wallace
and coworkers measured sensory thresholds with a
methodology that seems to be more complex than the
Method of Limits. Finally, Wallace and coworkers31
asked their participants to report ‘‘discomfort,’’ rather
than ‘‘pain’’ as we did.
A mean pain threshold measurement with VFMs
according to the Method of Limits protocol, in patients
with allodynia as a consequence of a neuropathic pain
syndrome, has not been published before. In this study,
we showed that, although the etiology and pathophysio-
logy of allodynia vary, quantiﬁcation of this symptom
with VFMs using the Method of Limits is simple
and practical in almost all the patients with allodynia
(20 of 22). Future studies are needed to evaluate the
response of these pain thresholds to therapeutic interven-
tions, in order to demonstrate that this method of QST
can also measure a change in (hyper) sensibility after the
treatment.
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